SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : THC -- Ignore unavailable to you. Want to Upgrade?


To: Herc who wrote (9)9/27/1999 11:34:00 AM
From: William L. Oppenheim  Respond to of 35
 
Where are you located. Academic Centers have it tougher because the case mix is often sicker, more poorly nourished, and more expensive, and because of the added expense of residents, and training in general. Now, they also seem to be run by folks, who instead of protecting what has been hard won in medicine--namely the patient doctor relationship, privacy, and the drive toward excellence--now have capitulated to the concepts of medicine for the masses, even if quality suffers. They say they have to compete with the HMOs on an equal basis, so they have no choice. They try to constrain the production of specialists, even when all of know that when having our mufflers replaced, we should go to a muffler shop, not the corner gas station. They buy up local practices and put their signs all over town, and they duplicate the same advertising as their competitors. Every dollar spent there is one less available for treatment or new facilities and technology. They emphasize volume over quality. Never mind that a large part of our economy has profitied by exporting our medical advances to the world. A sign of the times. It will take a generation or two to get over this, as it did in the more social countries when the medical system was allowed to gradually run down. And people will have to get a lot angrier first. The Hipprocratic Oath (? teacher's pet mentality) states that we must take care of those who present to us, but these companies circumvent that by taking advantage of those of us who believe in the Oath, and by refusing insurance to those who can't pay in the first place. I believe that one cannot turn a patient away, but we don't have the same obligation to a company. They are the ones who have a contract with their patients, not us. Unfortunately, Congress had tilted the game in their favor by refusing to allow us to organize and confront these entities for what they are. For-profit entities where every dollar of denied care winds up boosting their stock on Wall Street, where the real profits are made. They control access as well as the actual treatments which are available, and the doctors and patients are not allowed to hold them accountable. ERISA and anti trust acts protect them even as they create separate classes of individuals with different rights to recourse. Congress created these issues and now will itself be held accountable to solve them. Don't hold your breath.



To: Herc who wrote (9)5/2/2000 2:49:00 PM
From: Tunica Albuginea  Read Replies (2) | Respond to of 35
 
I am starting to look at Health Care for defensive plays
in what I see big interest rate increases ahead to slow
this superhot economy down.
Health Care is coming back with a vengeance.
RHB posted nice increases today and stock was up 3.5%.

THC has a 5 year growth rate of 28% which is now about the same as Dell's!!!

siliconinvestor.com

I am comparing THC to it's competitors.
You can see how it has a higher growth rate than
all, 376.71% !!!.
There is no reason why we could not go back to those numbers.
You can review other performance measures in Quicken.

The return on equity has been less but that is due to
Medicare budget cuts.
All this is changing now.
Money is starting to flow back into Health Care
because HMOs have a legal gun ( lawsuits ) put to
their heads to provide good care.

Merrill has a 1-1 opinion on THC, their highest and have a
12 month target of $44.

I believe it will.
At todays low price , that will be a nice return for a long term investor,

TA

==============================================
quicken.com

Compare stock to competitors

Click the numbered steps below for a detailed analysis of stocks that includes historical trends and industry comparisons.

1. GROWTH TRENDS 2. FINANCIAL HEALTH 3. MANAGEMENT PERFORMANCE 4. MARKET MULTIPLES 5. INTRINSIC VALUE 6. SUMMARY


Examine revenues (sales), net income (earnings), and cash flow to see how well a company is translating revenues into earnings, which are necessary for growth. Look for companies whose revenues, net income, and cash flow are rising steadily--or at faster rates than their competitors.
GROWTH EXPERT'S VIEW VALUE EXPERT'S VIEW FAQ

Revenues | Net Income | Cash Flow

Historical Revenue Linear | Logarithmic Annual | Quarterly


$ in millions 90 91 92 93 94 95 96 97 98 99
THC 3935 3806 3982 3761.8 2967 3318 5559 8691 9895 10880
COL 272.6 461 761.6 10252 11132 17695 19909 18819 18681 16657
RHB 38.4 44.5 48.4 61.7 83.2 89.4 104.6* 160.8 207.4 309.4
HRC 180.5 225.5 407 482.3 1127.4 1556.7 2436.5 3017.3 4006.1 4072.1

* Change in company fiscal year

Revenue Growth Rates 1 Year | 3 Years | 5 Years | 10 Years

Company Industry Sector S&P 500 Ranking*
THC 8.91% -3.22% 14.38% 18.55%
COL -11.73% -3.22% 14.38% 18.55%
RHB 49.18% -3.22% 14.38% 18.55%
HRC -1.6% 38.92% 14.38% 18.55%


THC
Revenue
THC's 1 year revenue growth is 376.71% higher than the industry average, which is usually a good sign. Compare THC's revenue growth to earnings growth to see how well THC is translating revenue into earnings.

COL
Revenue
COL's 1 year revenue growth is 264.29% lower than the industry average, which means the company is growing significantly slower than its peers. Compare COL's revenue growth to earnings growth to see if earnings are also lagging behind the industry average.

RHB
Revenue
RHB's 1 year revenue growth is 1627.33% higher than the industry average, which is usually a good sign. Compare RHB's revenue growth to earnings growth to see how well RHB is translating revenue into earnings.

HRC
Revenue
HRC's 1 year revenue growth is 104.11% lower than the industry average, which means the company is growing significantly slower than its peers. Compare HRC's revenue growth to earnings growth to see if earnings are also lagging behind the industry average.



Industry/Sector Information
Company Industry Sector
THC Hospitals Healthcare
COL Hospitals Healthcare
RHB Hospitals Healthcare
HRC Specialized Health Svcs Healthcare


Media General Financial Services price data reflect closing prices at the end of the last trading day. Company and industry data reflect latest reported filings with the SEC.